Prognostic role of myocardial storage, hypertrophy, and inflammation/fibrosis in Fabry cardiomyopathy: a new predictive score including T1 values
- 15 December 2025
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
Abstract
Aims: Limited data exist about the prognostic significance of the processes underlying Fabry Disease (FD) cardiomyopathy (storage, hypertrophy, inflammation/fibrosis) as detected by cardiac magnetic resonance (CMR). Notably, T1 mapping has had limited prognostic application primarily due to poor reproducibility across different sequences and vendors. This CMR study aimed to identify the prognostic weight of the different mechanisms of FD cardiomyopathy and to develop a predictive score of adverse cardiovascular (CV) events. Methods and results: This prospective, observational study enrolled 167 FD patients, who underwent CMR at baseline. The study endpoint was the composite of all-cause death, heart failure hospitalization, new-onset atrial fibrillation/flutter, non-sustained/sustained ventricular tachycardia, major bradyarrhythmias, and myocardial infarction with non-obstructive coronary arteries. Over a median follow-up of 40 months, 27 patients (16%) experienced the primary endpoint. Left ventricle mass index (LVMI) [HR 1.02 (1.02–1.03), P < 0.001], presence of late gadolinium enhancement (LGE) [HR 20.12 (6.02–67.24), P < 0.001] and its extent [number of LGE + segments: HR 1.51 (1.33–1.71), P < 0001], and septal T1 [HR 0.98 (0.97–0.99), <0.001], measured in both ShMOLLI and MOLLI sequences, were associated with the composite endpoint. None of the patients with normal T1 experienced adverse CV events. A multivariable model including age, LVMI, number of LGE+ segments, and T1 value showed a good performance in predicting the composite endpoint. Conclusion: We propose a 3-year prognostic score to predict CV outcome in FD, including age, LVMI, number of LGE+ segments, and septal T1. Normal T1 has a negative predictive value for adverse CV events irrespective of the acquisition setting.Keywords
Funding Information
- Ricerca Corrente
- Italian Ministry of Health
- IRCCS Policlinico San Donato
This publication has 22 references indexed in Scilit:
- Impact of cardiac magnetic resonance on the clinical management of patients with Fabry disease: Data from the CMR Italian research and CLinical nEtwork for Fabry disease (CIRCLE-FD)International Journal of Cardiology, 2025
- The Italian Fabry Disease Cardiovascular Registry (IFDCR)European Heart Journal - Quality of Care and Clinical Outcomes, 2024
- Correlations Between Cardiac Magnetic Resonance and Myocardial Histologic Findings in Fabry DiseaseJACC: Cardiovascular Imaging, 2023
- Validated Model for Prediction of Adverse Cardiac Outcome in Patients With Fabry DiseaseJACC, 2022
- 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac deathEuropean Heart Journal, 2022
- Cardiac Involvement in Fabry DiseaseJACC, 2021
- Cardiac Fabry Disease With Late Gadolinium Enhancement Is a Chronic Inflammatory CardiomyopathyJACC, 2016
- Relation of Burden of Myocardial Fibrosis to Malignant Ventricular Arrhythmias and Outcomes in Fabry DiseaseThe American Journal of Cardiology, 2014
- The Histological Basis of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in a Patient with Anderson-Fabry DiseaseJournal of Cardiovascular Magnetic Resonance, 2006
- Impact of Enzyme Replacement Therapy on Cardiac Morphology and Function and Late Enhancement in Fabry’s CardiomyopathyThe American Journal of Cardiology, 2006